Last reviewed · How we verify

Bupivacaine Injection

Ciusss de L'Est de l'Île de Montréal · FDA-approved active Small molecule Under review Quality 0/100

Bupivacaine Injection is a Local anesthetic (amide) Small molecule drug developed by Ciusss de L'Est de l'Île de Montréal. It is currently FDA-approved for Local anesthesia for infiltration, nerve block, epidural, and spinal anesthesia, Pain management in surgical and dental procedures. Also known as: evaluation of pain by using two different types of local anesthesia, Marcaine, Bupivacaine Hydrochloride Injection, stellate ganglion block.

Bupivacaine blocks sodium channels in nerve cell membranes, preventing the initiation and conduction of nerve impulses to produce local anesthesia.

Bupivacaine injection is a small molecule that acts as a sodium channel protein type IV alpha subunit blocker, classified as a blocker. It is used to treat various conditions including postoperative pain, postsurgical pain, chronic postoperative pain, post-thoracotomy pain syndrome, and scoliosis idiopathic, among others.

At a glance

Generic nameBupivacaine Injection
Also known asevaluation of pain by using two different types of local anesthesia, Marcaine, Bupivacaine Hydrochloride Injection, stellate ganglion block, Bupivacaine HCl (Marcaine 0.25% with epinephrine 1:200,000)
SponsorCiusss de L'Est de l'Île de Montréal
Drug classLocal anesthetic (amide)
TargetVoltage-gated sodium channels
ModalitySmall molecule
Therapeutic areaAnesthesia
PhaseFDA-approved

Mechanism of action

Bupivacaine is a long-acting amide local anesthetic that reversibly inhibits sodium influx into nerve fibers, stabilizing the neuronal membrane and raising the threshold for electrical excitability. This action prevents depolarization and propagation of action potentials, resulting in loss of sensation in the injected area. It has a longer duration of action compared to other local anesthetics due to its high lipophilicity and protein binding.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Bupivacaine Injection

What is Bupivacaine Injection?

Bupivacaine Injection is a Local anesthetic (amide) drug developed by Ciusss de L'Est de l'Île de Montréal, indicated for Local anesthesia for infiltration, nerve block, epidural, and spinal anesthesia, Pain management in surgical and dental procedures.

How does Bupivacaine Injection work?

Bupivacaine blocks sodium channels in nerve cell membranes, preventing the initiation and conduction of nerve impulses to produce local anesthesia.

What is Bupivacaine Injection used for?

Bupivacaine Injection is indicated for Local anesthesia for infiltration, nerve block, epidural, and spinal anesthesia, Pain management in surgical and dental procedures.

Who makes Bupivacaine Injection?

Bupivacaine Injection is developed and marketed by Ciusss de L'Est de l'Île de Montréal (see full Ciusss de L'Est de l'Île de Montréal pipeline at /company/ciusss-de-l-est-de-l-le-de-montr-al).

Is Bupivacaine Injection also known as anything else?

Bupivacaine Injection is also known as evaluation of pain by using two different types of local anesthesia, Marcaine, Bupivacaine Hydrochloride Injection, stellate ganglion block, Bupivacaine HCl (Marcaine 0.25% with epinephrine 1:200,000).

What drug class is Bupivacaine Injection in?

Bupivacaine Injection belongs to the Local anesthetic (amide) class. See all Local anesthetic (amide) drugs at /class/local-anesthetic-amide.

What development phase is Bupivacaine Injection in?

Bupivacaine Injection is FDA-approved (marketed).

What are the side effects of Bupivacaine Injection?

Common side effects of Bupivacaine Injection include Nervousness or anxiety, Dizziness or lightheadedness, Tinnitus, Tremor, Hypotension, Bradycardia.

What does Bupivacaine Injection target?

Bupivacaine Injection targets Voltage-gated sodium channels and is a Local anesthetic (amide).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing